title: [Candida fungemia].
abstract: From 1980 to 1986, 52 patients presented with an episode of fungemia due to Candida species at the Centre Hospitalier Universitaire Vaudois (representing 2% of the patients with positive blood cultures). In 51 of the 52 patients (98%) the infection was nosocomial, occurring after a median hospital stay of 24 days (range 4-250 days). Only 36 patients (69%) presented with an underlying condition (neoplasms in 18 patients, alcoholism in 7, diabetes in 6, immunosuppressive therapy in 5). In 19 patients (37%) an episode of bacteremia occurred prior to fungemia (median time 14 days, range 1-70 days). Candida albicans was the most commonly isolated species (71%). In 50 patients (96%) the episode of fungemia was associated with a significant, although nonspecific, clinical impairment. The digestive tract (38%) and N intravascular catheter (31%) were the two most common portals of entry for the fungemia. 32 patients (62%) received specific antifungal therapy consisting of amphotericin B in 29 patients (median total dose 450 mg, administered either alone or in association) or of ketoconazole in 3 patients. The global mortality was 46% and the fungemia-related mortality was 21%. Global and fungemia-related mortalities were significantly higher in patients not treated with antifungals than in those treated with them (87% versus 30%, p less than 0.001, and 47% versus 11%, p = 0.01 respectively).
authors.affiliation: Département de médecine interne, Centre hospitalier universitaire vaudois, Lausanne.
authors.forename: G
authors.initials: G
authors.lastname: Zanetti
authors.forename: T
authors.initials: T
authors.lastname: Calandra
authors.forename: B
authors.initials: B
authors.lastname: de Muralt
authors.forename: J
authors.initials: J
authors.lastname: Bille
authors.forename: M P
authors.initials: MP
authors.lastname: Glauser
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000666:Amphotericin B / Q000627:therapeutic use; D001769:Blood / Q000382:microbiology; D002176:Candida albicans / Q000302:isolation & purification; D002177:Candidiasis / Q000097:blood* / Q000188:drug therapy / Q000209:etiology; D002648:Child; D002675:Child, Preschool; D003428:Cross Infection / Q000382:microbiology; D005260:Female; D006801:Humans; D007654:Ketoconazole / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies
chemical_list: D000666:Amphotericin B; D007654:Ketoconazole
vernacular_title: Fongémies à Candida.